Biotech firm NUZ (ASX:NUZ) has secured backing from a key U.S. health agency to launch an expanded access program for its primary drug candidate.
This initiative aims to provide eligible Amyotrophic Lateral Sclerosis (ALS) patients with access to the experimental treatment outside of standard clinical trials.
Source Attribution: Article content originally reported by Special Report. Read original story coverage on Special Report →
